FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to new crystalline forms of acid addition salts of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, wherein the acid is specified in methanesulphonic, maleic, fumaric, citric, orotic, 10-camphor sulphonic acids and fencifose. The salts possess the agonist properties of neuronal nicotine receptor (NNR) and can be used for managing or preventing pain, an inflammation or a CNS disorder. Each of the crystalline salts is characterised by an X-ray powder diffraction diagram. The invention also involves an amorphous form of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine monocitrate and polymorphic forms of the above crystalline salts.
EFFECT: invention refers to a pharmaceutical composition containing an effective amount of the presented salts.
19 cl, 8 dwg, 33 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE | 2014 |
|
RU2700796C2 |
| 3-{(3R,4R)-4-METHYL-3-[METHYL-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)AMINO]PIPERIDIN-1-YL}-3-OXOPROPIONITRILE MONOCITRATE CRYSTALLINE FORM AND ITS USING | 2002 |
|
RU2315052C2 |
| NOVEL COMPOUNDS | 2009 |
|
RU2507197C2 |
| SALT CRYSTALS | 2013 |
|
RU2652116C2 |
| 3-PHENOXYMETHYL-PYRROLIDINE COMPOUNDS | 2010 |
|
RU2535669C2 |
| USEFUL PHARMACEUTICAL SALTS OF 7-[(3R,4R)-3-HYDROXY-4-HYDROXYMETHYL-PYRROLIDINE-1-YLMETHYL]-3,5-DIHYDRO-PYRROLO[3,2-D] PYRIMIDINE-4-ONE | 2010 |
|
RU2489435C2 |
| 9E-15-(2-PYRROLIDIN-1-YL-ETHOXY)-7,12,25-TRIOXA-19,21,24-TRIAZATETRACYCLO[18.3.1.1(2,5). 1(14,18)]HEXACOSA-1(24),2,4,9,14,16,18(26),20,22-NONAENE CITRATE SALT | 2010 |
|
RU2543721C2 |
| SALTS OF EPIDERMAL GROWTH FACTOR RECEPTOR KINASE | 2013 |
|
RU2711077C2 |
| CRYSTALLINE FORM (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE HYDROSULPHATE | 2015 |
|
RU2723990C2 |
| CONDENSED RING HETEROARYL COMPOUNDS AND USE THEREOF AS TRK INHIBITORS | 2015 |
|
RU2708674C2 |
